# Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07524452** · PHASE3 · RECRUITING · sponsor: **Ming-Yuan Chen** · enrollment: 430 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant and Adjuvant Becotatug Vedotin
- **DRUG:** Neoadjuvant and Adjuvant Immunotherapy
- **PROCEDURE:** Surgery
- **RADIATION:** Adjuvant Radiotherapy
- **DRUG:** Adjuvant Cisplatin

## Key facts

- **NCT ID:** NCT07524452
- **Lead sponsor:** Ming-Yuan Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-06
- **Primary completion:** 2031-02-28
- **Final completion:** 2032-02-28
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07524452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07524452, "Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07524452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*